These are the stocks posting the largest moves in midday trading.…
The FDA approval of Eli Lillys GLP-1 pill Foundayo comes nearly three months after Novo Nordisks oral version of Wegovy…
The U.S. Food and Drug ?Administration on Wednesday approved Eli Lillys weight-loss pill, making it the second to market after…
…
Eli Lilly and Co (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults…
Barclays reiterates Eli Lilly stock Overweight on acquisition…
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
Eli Lilly said on Tuesday it would buy Centessa ?Pharmaceuticals ?in ?a deal valued at up to $7.8 billion.…
Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and…
Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly ?prices…
Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash,…
The healthcare stock may not be running out of growth catalysts anytime soon.…
Eli Lilly baut sein Portfolio im Bereich der KI-gestützten Wirkstoffforschung durch eine bis zu 2,75 Mrd. USD schwere Vereinbarung mit…
Eli Lilly and Co (NYSE:LLY) has entered into a drug discovery collaboration with Insilico Medicine, a clinical-stage biotechnology firm focused…
Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldnt count the company out.…
Eli Lillys $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven…
…
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the…
Eli Lilly is much more than just a weight loss stock.…
Its not much of a contest right now.…
Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.…
The latest trading day saw Eli Lilly (LLY) settling at $916.31, representing a +1.47% change from its previous close.…
After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.…
Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising…
More than 80 global executives traveled to Beijing this weekend for the state-organized China Development Forum.…
Eli Lillys stock has been receiving many upgrades after posting strong quarterly results in February.…
Earlier in March 2026, Hims & Hers Health announced that Kathryn Beiser, a veteran of Discover, Kaiser Permanente, Eli Lilly,…
A catalyst for stock performance may be just ahead.…
Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment…
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to…
…
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Cos (NYSE:LLY) experimental weight-loss…
NASDAQ: MTVALili Elston: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host,…
Both have plenty to offer investors, but one has a better outlook.…
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.…
Eli Lillys GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.…
Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound…
Eli Lilly and Co (NYSE:LLY) has reported positive results from its late-stage trial of retatrutide, a next-generation obesity drug, demonstrating...…
…
Each of these companies could benefit from this high-growth market over time.…
Eli Lilly has spent the last decade transforming from a reliable but unremarkable dividend payer into one of the most…
Eli Lilly (LLY) concluded the recent trading session at $930.5, signifying a -5.93% move from its prior days close.…
Here are some of the stocks making big headlines in midday trading.…
These are the stocks posting the largest moves premarket.…
Eli Lillys stock price is based on growth rates that might fall short.…
Eli Lilly, Tencent Music among market cap stock movers on Tuesday…
Eli Lillys stock is down this year, and its high valuation may be a big reason why.…
Eli Lilly and Company (NYSE:LLY) is one of the most profitable blue chip stocks to invest in now. Reuters reported…
It wont be easy to knock the company off its pedestal.…
LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to…